Mira Pharmaceuticals Azioni (NASDAQ: MIRA)

Ultime notizie per Mira Pharmaceuticals (NASDAQ:MIRA) Azioni

Mira Pharmaceuticals

Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals Inc

MIRAI Corp

MIRAIT One Corp

MIRAMAR RESOURCES LTD by MIRAMAR RESOURCES LTD

MIRATI THERAPEUTICS INC COM

MIRACLE ENTMT INC by Miracle Entertainment Inc.

Miracle Entertainment Inc

MIRAGE ENERGY CORP by Mirage Energy Corporation

Mirage Energy Corp

MIRAMAR HOTE & INVST CO by Miramar Hotel & Investment Co., Ltd.

Miramar Hotel & Investment Co Ltd

TAKARA LEBEN CO LTD by Takara Leben Co., Ltd.

Mirarth Holdings Inc

MIRASOL RESOURCES LTD by Mirasol Resources Ltd.

Mirasol Resources Ltd

Miratap Inc

MIRAVANT MEDICAL TECHS by Miravant Medical Technologies

Miravant Medical Technologies

Citigroup analyst Patrick Donnelly maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Buy and raises the price target from $155 to $190.

News

Price Target

Analyst Ratings

ILMN

Citigroup Maintains Buy on Illumina, Raises Price Target to $190

Needham analyst Mike Cikos reiterates DigitalOcean Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCN#NYSE">DOCN</a>) with a Hold.

Reiteration

DOCN

Needham Reiterates Hold on DigitalOcean Holdings

Citigroup analyst Daniel Grosslight maintains Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) with a Buy and lowers the price target from $21 to $18.5.

Citigroup Maintains Buy on Owens & Minor, Lowers Price Target to $18.5

Deutsche Bank analyst Benjamin Black maintains Webtoon Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBTN#NASDAQ">WBTN</a>) with a Buy and lowers the price target from $18 to $16.

WBTN

Deutsche Bank Maintains Buy on Webtoon Entertainment, Lowers Price Target to $16

Deutsche Bank analyst Benjamin Soff maintains New York Times (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYT#NYSE">NYT</a>) with a Buy and raises the price target from $65 to $66.

Deutsche Bank Maintains Buy on New York Times, Raises Price Target to $66

Deutsche Bank analyst Ross Seymore maintains Navitas Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) with a Buy and lowers the price target from $6 to $4.

NVTS

Deutsche Bank Maintains Buy on Navitas Semiconductor, Lowers Price Target to $4

Needham analyst Serge Belanger reiterates BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Buy and maintains $14 price target.

BCRX

Needham Reiterates Buy on BioCryst Pharma, Maintains $14 Price Target

Citigroup analyst Jason Bazinet maintains Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) with a Buy and raises the price target from $53 to $63.

RBLX

Citigroup Maintains Buy on Roblox, Raises Price Target to $63

Biotech

General

MAIA

MAIA Biotechnology To Present Late-Breaking THIO-101 Phase 2 Trial Updates On THIO And Cemiplimab Combo In NSCLC At SITC 2024, Highlighting Long-Term Therapeutic Benefits Beyond Treatment Cessation

Citigroup analyst Yigal Nochomovitz maintains Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) with a Neutral and raises the price target from $204 to $206.

KRYS

Citigroup Maintains Neutral on Krystal Biotech, Raises Price Target to $206

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points on Tuesday.
Following the market opening Tuesday, the Dow traded up 0.22% to 41,887.70 while the NASDAQ rose 0.70% to 18,307.76. The S&amp;P 500 also rose, gaining, 0.50% to 5,741.41.
Check This Out: <a href="https://www.benzinga.com/news/24/11/41741538/wall-streets-most-accurate-analysts-spotlight-on-3-financial-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Financial Stocks Delivering High-Dividend Yields</a>
Leading and Lagging Sectors Information technology shares rose by 0.9% on Tuesday.
In trading on Tuesday, health care shares fell by 0.3%.
Top Headline
The trade deficit in the U.S. increased to $84.4 billion in September, recording the highest level since April 2022, and above market estimates of a $84.1 billion gap, versus a revised $70.8 billion gap in August.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Bionomics Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) shares shot up 190% to $0.5583 after the company announced it secured an AUS$1 million milestone payment from Carina Biotech for its BNC101 oncology program, with the potential to earn up to AUS$118 million.</li>
<li>Shares of Avalon GloboCare Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALBT#NASDAQ">ALBT</a>) got a boost, surging 68% to $3.78.</li>
<li>ZyVersa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) shares were also up, gaining 60% to $2.92 after the company highlighted data showing the potential of inflammasome inhibition to protect pancreatic islet beta cells and attenuate progression from obesity to insulin resistance and type 2 diabetes.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Marqeta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MQ#NASDAQ">MQ</a>) shares dropped 36% to $3.79 after the company reported worse-than-expected Q3 sales results. Also, multiple firms downgraded their respective ratings on the company and lowered their respective price targets.</li>
<li>Shares of Verrica Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) were down 36% to $0.91 following downbeat quarterly results.</li>
<li>Bioventus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BVS#NASDAQ">BVS</a>) was down, falling 36% to $8.77 after the company announced third-quarter results.</li>
</ul>
Commodities In commodity news, oil traded up 0.6% to $71.92 while gold traded up 0.3% at $2,754.40.
Silver traded up 0.8% to $32.880 on Tuesday, while copper rose 1.1% to $4.4795.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 fell 0.1%, Germany's DAX gained 0.2% and France's CAC 40 rose 0.2%. Spain's IBEX 35 Index rose 0.1%, while London's FTSE 100 fell 0.2%.
Spain's consumer confidence indicator declined by 4.6 points to a reading of 84.8 in September.
Asia Pacific Markets
Asian markets closed higher on Tuesday, with Japan's Nikkei 225 gaining 1.11%, Hong Kong's Hang Seng Index gaining 2.14%, China's Shanghai Composite Index gaining 2.32% and India's BSE Sensex gaining 0.88%.
Economics
The trade deficit in the U.S. increased to $84.4 billion in September, recording the highest level since April 2022, and above market estimates of a $84.1 billion gap, versus a revised $70.8 billion gap in August.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41743859/top-3-consumer-stocks-that-may-keep-you-up-at-night-this-quarter">Top 3 Consumer Stocks That May Keep You Up At Night This Quarter</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

Markets

ALBT

BNOX

VRCA

ZVSA

Nasdaq Gains Over 100 Points; US Trade Deficit Widens In September

Trading Ideas

ZCAR

Zoomcar Holdings Shares Halted To The Upside; Stock Now Up 31.51%

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) with a Buy and maintains $6 price target.

LXRX

HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $6 Price Target

A widely watched gauge of bond market volatility has surged to its highest level in over a year as American voters cast their ballots in one of the closest presidential <a href="https://www.benzinga.com/topic/2024-election">races in recent history. </a>
The ICE BofAML U.S. Bond Market Option Volatility Estimate Index, or &#8220;MOVE&#8221; index, closed at 136 on Monday, reaching levels last seen in early October 2023. 
This spike in the MOVE index highlights mounting anxiety in the bond market, driven by political uncertainty and fears of inflationary fiscal policies.
<h3 class="wp-block-heading">What Is The MOVE Index?</h3>
The MOVE index, often described as the VIX for bonds, measures expected volatility in the Treasury market based on options pricing. 
Like the VIX, which tracks volatility in the equity market, the MOVE index is seen as a &#8220;fear gauge&#8221; for fixed-income investors. 
Higher MOVE readings indicate increased uncertainty about future bond price movements, reflecting traders&#8217; fears around interest rates, inflation, and broader economic conditions.
See Also: <a href="https://www.benzinga.com/money/guide-to-volatility-indices-vix">Beginners Guide to VIX or Volatility Indices</a>
<h3 class="wp-block-heading">Election Jitters Fuel Bond Market Anxiety</h3>
The U.S. presidential election has investors on edge, with polls showing one of the tightest races in modern American history. 
Neither Vice President Kamala Harris nor ex-President Donald Trump held a meaningful lead in critical battleground states ahead of Nov. 5, <a href="https://www.nytimes.com/interactive/2024/us/elections/polls-president.html">wrote</a> Nate Cohn, chief political analyst at the New York Times. 
&#8220;In the history of modern polling, there's never been a campaign where the final polls showed such a close contest,&#8221; he added.
The possibility of a prolonged, contentious result has amplified concerns in the bond market, where volatility has jumped 51% since late September. 
Fixed-income investors are also weighing the potential fiscal impact of each candidate&#8217;s policies, especially if the winner's administration fuels inflation and adds to the federal debt.
According to the Committee for a Responsible Federal Budget (CRFB), Trump's spending plans could increase the national debt by $7.75 trillion over the next decade, driving the debt-to-GDP ratio to 143% by 2035. By contrast, Kamala Harris's proposals would add $3.95 trillion to the debt, resulting in a debt-to-GDP ratio of approximately 134% by the same year.
Chart: Bond Volatility Index Has Risen By Over 50% Since Late-September
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="501" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05084449/image-31-1024x501.png" alt="" class="wp-image-630321" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05084449/image-31-1024x501.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05084449/image-31-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05084449/image-31-768x376.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05084449/image-31-1536x752.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05084449/image-31.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h3 class="wp-block-heading">Trump's Tariff Plans Stoke Inflation Fears</h3>
Under a Trump administration, inflation could rise if proposed tariffs on Chinese imports and other goods come into effect. 
Trump has floated a 60% tariff on Chinese products and a universal 10% tariff, policies which JPMorgan analysts estimate could drive inflation up by as much as 2.4% in a worst-case scenario. 
&#8220;Tariffs are inflationary,&#8221; IMF deputy managing director Gita Gopinath warned in October.
With inflation a growing concern, Treasury yields have been on an upward trajectory, as investors demand higher returns to offset potential future price increases. 
Yields on the 10-year Treasury bond have risen by 50 basis points last month and hit 4.33% on Tuesday. 
<h3 class="wp-block-heading">&#8216;Bond Vigilantes&#8217; Are Back</h3>
The bond market&#8217;s reaction to these uncertainties has been swift and severe. 
&#8220;Nothing seems to be stopping U.S. Treasury bond yields from rising,&#8221; said veteran Wall Street investor Ed Yardeni. 
&#8220;The Bond&nbsp;Vigilantes&nbsp;have been voting early (and voting often) by selling US Treasury notes and bonds,&#8221; he added. 
The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>), which tracks long-dated Treasuries, fell nearly 6% in October 2024.
With both candidates likely to enact substantial stimulus, Yardeni stated, &#8220;The bond market is tightening the economy itself,&#8221; as investors anticipate inflation and higher interest rates. 
Yardeni indicated this surge in yields could push the 10-year Treasury into the 5% range, a level not seen since before the financial crisis.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41740288/us-stocks-set-for-cautious-start-as-investors-brace-for-volatility-on-election-day-expert-points-to">US Stocks Set For Cautious Start As Investors Brace For Volatility On Election Day: Expert Points To &#8216;Pretty Well Overall&#8217; Historical Performance</a></li>
</ul>
Image: Shutterstock

Analyst Color

Macro Economic Events

Bonds

Specialty ETFs

Politics

Treasuries

Econ #s

Economics

ETFs

iShares Trust Barclays 20+ Year Treasury Bond Fund

Bond Market Fear Gauge Soars To 1-Year High Ahead Of US Election Results: 'Bond Vigilantes Have Been Voting Early'

Deutsche Bank analyst Benjamin Soff maintains Live Nation Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) with a Buy and raises the price target from $122 to $130.

Deutsche Bank Maintains Buy on Live Nation Entertainment, Raises Price Target to $130

WIIM

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are higher amid the US presidential election.

<a href="https://x.com/WolfpackReports/status/1853809784731873633" title="https://x.com/WolfpackReports/status/1853809784731873633">https://x.com/WolfpackReports/status/1853809784731873633</a>

Shares Of MediaAlpha See Volume; Wolfpack Research Thread On X, "We warned everyone about $MAX and the FTC investigation…"

Market Summary

PLTR

Benzinga Market Summary: Global Markets On Watch Amid US Presidential Election, Gold And Oil Move Higher, Palantir Surges On Strong Guidance

Investors with a lot of money to spend have taken a bullish stance on Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with META, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 31 uncommon options trades for Meta Platforms.
This isn't normal.
The overall sentiment of these big-money traders is split between 38% bullish and 35%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $641,951, and 26 are calls, for a total amount of $1,896,313.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $400.0 to $820.0 for Meta Platforms over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Meta Platforms stands at 2470.58, with a total volume reaching 12,875.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Meta Platforms, situated within the strike price corridor from $400.0 to $820.0, throughout the last 30 days.
<h3>Meta Platforms Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730817964_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>META</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$11.8</td>
<td>$11.6</td>
<td>$11.68</td>
<td>$540.00</td>
<td>$274.7K</td>
<td>5.6K</td>
<td style="text-align: right;">419</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$11.65</td>
<td>$11.45</td>
<td>$11.56</td>
<td>$610.00</td>
<td>$271.9K</td>
<td>2.3K</td>
<td style="text-align: right;">438</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$82.15</td>
<td>$81.6</td>
<td>$82.15</td>
<td>$500.00</td>
<td>$164.3K</td>
<td>12.0K</td>
<td style="text-align: right;">22</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$83.35</td>
<td>$82.15</td>
<td>$82.1</td>
<td>$500.00</td>
<td>$164.2K</td>
<td>12.0K</td>
<td style="text-align: right;">22</td>
</tr>
<tr>
<td>META</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$253.4</td>
<td>$252.2</td>
<td>$253.4</td>
<td>$820.00</td>
<td>$152.0K</td>
<td>11</td>
<td style="text-align: right;">6</td>
</tr>
</tbody>
</table>

<h3>About Meta Platforms</h3>
Meta is the largest social media company in the world, boasting close to 4 billion monthly active users worldwide. The firm's "Family of Apps," its core business, consists of Facebook, Instagram, Messenger, and WhatsApp. End users can leverage these applications for a variety of different purposes, from keeping in touch with friends to following celebrities and running digital businesses for free. Meta packages customer data, gleaned from its application ecosystem and sells ads to digital advertisers. While the firm has been investing heavily in its Reality Labs business, it remains a very small part of Meta's overall sales.
In light of the recent options history for Meta Platforms, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Meta Platforms Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 5,457,256, with META's price down by -1.21%, positioned at $560.29.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 86 days.</li>
</ul>
<h3>Professional Analyst Ratings for Meta Platforms</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $665.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Raymond James continues to hold a Strong Buy rating for Meta Platforms, targeting a price of $650. 
&#x2A; Maintaining their stance, an analyst from Truist Securities continues to hold a Buy rating for Meta Platforms, targeting a price of $650. 
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for Meta Platforms, targeting a price of $650. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $670. 
&#x2A; An analyst from Citigroup persists with their Buy rating on Meta Platforms, maintaining a target price of $705. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Meta Platforms options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Looking At Meta Platforms's Recent Unusual Options Activity

Investors with a lot of money to spend have taken a bullish stance on Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with BKNG, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Booking Holdings.
This isn't normal.
The overall sentiment of these big-money traders is split between 77% bullish and 0%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $53,435, and 7 are calls, for a total amount of $528,728.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $3600.0 and $5750.0 for Booking Holdings, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Booking Holdings's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Booking Holdings's whale activity within a strike price range from $3600.0 to $5750.0 in the last 30 days. 
<h3>Booking Holdings Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730817959_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1248.0</td>
<td>$1232.0</td>
<td>$1248.0</td>
<td>$3600.00</td>
<td>$124.8K</td>
<td style="text-align: right;">337</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$1227.7</td>
<td>$1205.5</td>
<td>$1218.0</td>
<td>$3600.00</td>
<td>$121.8K</td>
<td style="text-align: right;">24</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$467.6</td>
<td>$442.6</td>
<td>$459.59</td>
<td>$4410.00</td>
<td>$91.9K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$818.9</td>
<td>$800.0</td>
<td>$818.9</td>
<td>$4150.00</td>
<td>$81.8K</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$492.8</td>
<td>$488.6</td>
<td>$492.8</td>
<td>$4600.00</td>
<td>$49.2K</td>
<td style="text-align: right;">17</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>

<h3>About Booking Holdings</h3>
Booking is the world's largest online travel agency by sales, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates several branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
After a thorough review of the options trading surrounding Booking Holdings, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Booking Holdings Standing Right Now?</h3>
<ul>
<li>With a trading volume of 3,661, the price of BKNG is down by -0.14%, reaching $4770.0.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 107 days from now.</li>
</ul>
<h3>What The Experts Say On Booking Holdings</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $4852.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Goldman Sachs has decided to maintain their Neutral rating on Booking Holdings, which currently sits at a price target of $4510. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Booking Holdings with a target price of $4600. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Booking Holdings with a target price of $5250. 
&#x2A; An analyst from Oppenheimer has decided to maintain their Outperform rating on Booking Holdings, which currently sits at a price target of $5000. 
&#x2A; Consistent in their evaluation, an analyst from Piper Sandler keeps a Neutral rating on Booking Holdings with a target price of $4900. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Booking Holdings with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

BKNG

A Closer Look at Booking Holdings's Options Market Dynamics

An update from MIRA Pharmaceuticals, Inc. (MIRA) is now available. MIRA Pharmaceuticals has approved a significant amendment to CEO Erez Aminov's e...

MIRA Pharmaceuticals Enhances CEO's Compensation Package

The latest update is out from MIRA Pharmaceuticals, Inc. (MIRA). MIRA Pharmaceuticals has revised its employment agreement with CFO Michelle Yanez,...

MIRA Pharmaceuticals Adjusts CFO Salary, Sets Annual Meeting

MIRA stock rallies 154% on preclinical results for ketamine drug

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
MIRA Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/mira-stock-quote/">MIRA</a>) stock is seeing massive gains on Monday after the pre-clinical-stage pharmaceutical company released data from its pre-clinical study of Ketamir-2.



Ketamir-2. is MIRA Pharmaceuticals&rsquo; novel oral ketamine analog. It&rsquo;s being studied as a potential <a href="https://finance.yahoo.com/news/mira-pharmaceuticals-reveals-preclinical-success-120000778.html">treatment for neurological and neuropsychiatric disorders</a>. That includes depression, treatment-resistant depression and post-traumatic stress disorder (PTSD).



Here&rsquo;s what MIRA Pharmaceuticals chairman and CEO Erez Aminov said about the new data.




&ldquo;Our vision at MIRA is to transform the treatment landscape for neurological and neuropsychiatric disorders. Ketamir-2 shows great promise in addressing these debilitating conditions with improved efficacy and safety, offering new hope and better quality of life for patients and their families. Importantly, we are seeing a drumbeat of promising data this year that we hope will allow us to file an IND and begin to test our theories about Ketamir-2 in actual patients in the near term.&rdquo;




<h2>What This Means for MIRA Stock</h2>



MIRA stock could benefit greatly if the company is able to move forward with its IND plans. The company&rsquo;s shares are already gaining today with more than 116 million shares traded. For the record, its daily average trading volume is about 654,000 shares.



MIRA Stock is up 318.1% as of Monday afternoon.



Investors will want to stick around for more of the most recent stock market stories!



We have all of the hottest stock market news investors need to know about on Monday! Among that is what has shares of Nio&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/nio-stock-quote/">NIO</a>), Reddit&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/rddt-stock-quote/">RDDT</a>) and Cassava Sciences&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/sava-stock-quote/">SAVA</a>) stock moving today. All of that info is good to go at the links below!



<h2>More Monday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/07/nio-stock-alert-more-details-emerge-about-upcoming-nio-day-2024/">NIO Stock Alert: More Details Emerge About Upcoming Nio Day 2024</a></li>



<li><a href="https://investorplace.com/2024/07/rddt-stock-alert-reddit-nabs-new-deals-with-nfl-nba/">RDDT Stock Alert: Reddit Nabs New Deals with NFL, NBA</a></li>



<li><a href="https://investorplace.com/2024/07/sava-stock-alert-cassava-sciences-pops-on-late-stage-trial-update/">SAVA Stock Alert: Cassava Sciences Pops on Late-Stage Trial Update</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/why-is-mira-pharmaceuticals-mira-stock-up-318-today/">Why Is MIRA Pharmaceuticals (MIRA) Stock Up 318% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is MIRA Pharmaceuticals (MIRA) Stock Up 318% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are a hot topic that traders are going to want to know about and we have all of the latest news on Tuesday morning!



Moving stocks this morning are earnings reports, a settlement agreement, the pricing of a public offering and more.



Let&rsquo;s get into that below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Warrantee (NASDAQ:<a href="https://investorplace.com/stock-quotes/wrnt-stock-quote/">WRNT</a>) stock is rocketing close to 254% alongside heavy pre-market trading.</li>



<li>Nature&rsquo;s Miracle (NASDAQ:<a href="https://investorplace.com/stock-quotes/nmhi-stock-quote/">NMHI</a>) shares are soaring more than 122% with strong early morning trading.</li>



<li>Volato (NYSEMKT:<a href="https://investorplace.com/stock-quotes/soar-stock-quote/">SOAR</a>) stock is surging nearly 78% with heavy early morning trading today.</li>



<li>Frequency Electronics (NASDAQ:<a href="https://investorplace.com/stock-quotes/feim-stock-quote/">FEIM</a>) shares are rising almost 33% alongside its <a href="https://www.marketwatch.com/story/frequency-electronics-shares-climb-on-higher-4q-earnings-a32189da">Q4 earnings report</a>.</li>



<li>Mammoth Energy Services (NASDAQ:<a href="https://investorplace.com/stock-quotes/tusk-stock-quote/">TUSK</a>) stock is heading over 29% higher after <a href="https://www.nasdaq.com/press-release/cobra-acquisitions-llc-announces-settlement-agreement-prepa-2024-07-22">announcing a settlement agreement</a>.</li>



<li>ENGlobal (NASDAQ:<a href="https://investorplace.com/stock-quotes/eng-stock-quote/">ENG</a>) shares are gaining more than 22% without any clear news.</li>



<li>Wheeler Real Estate IT (NASDAQ:<a href="https://investorplace.com/stock-quotes/whlr-stock-quote/">WHLR</a>) stock is jumping over 20% with no news to report.</li>



<li>Greenlane (NASDAQ:<a href="https://investorplace.com/stock-quotes/gnln-stock-quote/">GNLN</a>) shares are climbing more than 19% despite a lack of news on Tuesday.</li>



<li>SCYNEXIS (NASDAQ:<a href="https://investorplace.com/stock-quotes/scyx-stock-quote/">SCYX</a>) stock is getting an over 15% boost on a <a href="https://www.nasdaq.com/press-release/scynexis-receive-10-million-milestone-payment-gsk-triggered-delivery-completed-furi">$10 million milestone payment</a>.</li>



<li>Professional Diversity (NASDAQ:<a href="https://investorplace.com/stock-quotes/ipdn-stock-quote/">IPDN</a>) shares are up more than 13% on Tuesday morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>TransCode Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/rnaz-stock-quote/">RNAZ</a>) stock is crashing more than 59% after <a href="https://www.nasdaq.com/press-release/transcode-therapeutics-inc-announces-pricing-public-offering-2024-07-22">pricing a public offering</a>.</li>



<li>Mira Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/mira-stock-quote/">MIRA</a>) shares are plummeting close to 31% <a href="https://investorplace.com/2024/07/why-is-mira-pharmaceuticals-mira-stock-up-318-today/">after a massive rally yesterday</a>.</li>



<li>Brera (NASDAQ:<a href="https://investorplace.com/stock-quotes/brea-stock-quote/">BREA</a>) stock is diving nearly 25% with strong pre-market trading this morning.</li>



<li>CareMax (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmax-stock-quote/">CMAX</a>) shares are tumbling over 22% <a href="https://www.benzinga.com/news/24/07/39892411/caremax-shares-are-up-by-more-than-200-what-you-need-to-know">after a rally yesterday</a>.</li>



<li>Nukkleus (NASDAQ:<a href="https://investorplace.com/stock-quotes/nukk-stock-quote/">NUKK</a>) stock is taking a more than 19% beating after a recent rally.</li>



<li>Castellum (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ctm-stock-quote/">CTM</a>) shares are sliding over 19% <a href="https://investorplace.com/2024/07/why-is-castellum-ctm-stock-moving-today/">alongside volatility yesterday</a>.</li>



<li>Exicure (NASDAQ:<a href="https://investorplace.com/stock-quotes/xcur-stock-quote/">XCUR</a>) stock is falling almost 16% as shares <a href="https://investorplace.com/2024/07/why-is-exicure-xcur-stock-down-27-today/">continue to come off a recent rally</a>.</li>



<li>Quoin Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/qnrx-stock-quote/">QNRX</a>) shares are dropping more than 15% today.</li>



<li>Polaris (NYSE:<a href="https://investorplace.com/stock-quotes/pii-stock-quote/">PII</a>) stock is slipping over 15% after <a href="https://www.marketwatch.com/story/polaris-stock-tumbles-11-after-earnings-fall-far-short-of-consensus-and-company-cuts-full-year-outlook-c3299335">missing earnings estimates</a>.</li>



<li>Netcapital (NASDAQ:<a href="https://investorplace.com/stock-quotes/ncpl-stock-quote/">NCPL</a>) shares close out our pre-market stock movers down more than 14%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-july-23rd/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Mira Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/mira-stock-quote/">MIRA</a>) stock is down on Tuesday as the clinical-stage pharmaceutical company&rsquo;s shares come off of a major rally on Monday.



Shares of MIRA stock closed out Monday&rsquo;s normal trading hours up 627.4%. That came alongside heavy trading with <a href="https://finance.yahoo.com/quote/MIRA/">more than 153 million shares traded</a>. For comparison, its daily average trading volume is about 3.2 million shares.



Mira Pharmaceuticals stock experienced this rally after releasing data from a <a href="https://investorplace.com/2024/07/why-is-mira-pharmaceuticals-mira-stock-up-318-today/">pre-clinical study of Ketamir-2</a>. This is the company&rsquo;s novel oral ketamine analog designed to treat neurological and neuropsychiatric disorders.



The big news here is that the results were positive. This has the company excited about the prospect of furthering the development of Ketamir-2 and submitting an investigational new drug (IND) application for it.



<h2>MIRA Stock Movement on Tuesday</h2>



Considering the massive rally MIRA shares underwent yesterday, it makes sense they would give up some of those gains in the days to follow. This has the stock dropping 27.4% as of Tuesday morning.



Today&rsquo;s dip comes with more than 5.5 million shares changing hands this morning. That&rsquo;s already above its daily average trading volume but is well below yesterday&rsquo;s heavy trading.



Investors who are seeking out even more of the most recent stock market stories today will want to keep reading!



We have all of the hottest stock market news that traders need to know about on Tuesday! That includes everything happening with shares of TransCode Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/rnaz-stock-quote/">RNAZ</a>) stock, Nature&rsquo;s Miracle&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/nmhi-stock-quote/">NMHI</a>)&nbsp;stock and Warrantee&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/wrnt-stock-quote/">WRNT</a>) stock today. All of this info is ready to go at the links below!



<h2>More Stock Market News for Tuesday</h2>



<ul><li><a href="https://investorplace.com/2024/07/why-is-transcode-therapeutics-rnaz-stock-down-62-today/">Why Is TransCode Therapeutics (RNAZ) Stock Down 62% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/trade-of-the-day-buy-sentinelone-s-stock-amid-cybersecurity-carnage/">Trade of the Day: Buy SentinelOne (S) Stock Amid Cybersecurity Carnage</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-natures-miracle-nmhi-stock-up-94-today/">Why Is Nature&rsquo;s Miracle (NMHI) Stock Up 94% Today?</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/why-is-mira-pharmaceuticals-mira-stock-down-27-today/">Why Is Mira Pharmaceuticals (MIRA) Stock Down 27% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Mira Pharmaceuticals (MIRA) Stock Down 27% Today?

Earnings Week Ahead: Walmart, Home Depot, Alibaba, Cisco and more

MIRA Mira Pharmaceuticals files $100M mixed securities shelf

MIRA Pharmaceuticals files $100M mixed securities shelf

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Mira Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/mira-stock-quote/">MIRA</a>) just reported results for the second quarter of 2024.<ul><li>Mira Pharmaceuticals reported earnings per share of -11 cents. This was below the analyst estimate for EPS of -10 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/mira-stock-earnings-mira-pharmaceuticals-for-q2-of-2024/">MIRA Stock Earnings: Mira Pharmaceuticals Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

MIRA Stock Earnings: Mira Pharmaceuticals Misses EPS for Q2 2024

AMAT

ASTS

ASXC

ATOS

BABA

BATL

BEEM

BEKE

BLDP

BLUE

BREA

CARA

CATX

CMAX

COCP

CSCO

CTRM

ESPR

FEIM

GLNG

GNLN

GOEV

GOLD

GRAB

HUYA

IPDN

JAGX

KNDI

LITE

MDAI

MIRA

MMAT

MNDY

NCPL

NMHI

NNDM

NUKK

OGEN

OUST

PSFE

QNRX

RDDT

RNAZ

RRAC

SACH

SAVA

SCYX

SOAR

STNE

TAYD

TCEHY

TCRT

TUSK

VUZI

WHLR

WKHS

WRNT

XXII

Screenshot 2024-10-02 at 5.44.40 PM

Breakthrough Therapies And Novel Treatments - This Biopharma Is Out To Change The Game

Screenshot 2024-09-18 at 6.27.57 PM

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing On Early Clinical Efficacy Demonstration For Neuropathic Pain In 2025

Screenshot 2024-09-04 at 6.19.41 PM

TELO

Telomir Pharmaceuticals (NASDAQ: TELO) Featured In Local ABC Exclusive Showing Positive Outcomes Of Proposed Age Reversal Pill In Dogs

Screenshot 2024-08-26 at 4.53.37 PM

The Potential Of Ketamir-2: A Safer Treatment For Mental Health Disorders And Neuropathic Pain, IND Filing Expected By Year-End

Screenshot 2024-07-25 at 6.08.16 PM

MIRA Pharmaceuticals (NASDAQ: MIRA) Reports Promising Pre-Clinical Trial Results For Mental Health Treatment, To Submit Investigational New Drug Application By End Of Year

Press Releases

MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study

MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025

MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024

MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study

MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain

Comments

Mira Pharmaceuticals

Notizie

Ultime notizie per Mira Pharmaceuticals (NASDAQ:MIRA) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO